Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceGut health

Butyrate (Tributyrin)

Butyrate is unquestionably important biology — it is the primary fuel for colonocytes — but oral supplements are a weak way to deliver it, and the human trial evidence is small, short and mostly on surrogate endpoints rather than symptoms.

What the science says

  • Improves symptoms in inflammatory bowel disease Limited evidence

    A randomised placebo-controlled multicentre trial of microencapsulated sodium butyrate in children and adolescents with newly diagnosed IBD found no significant benefit on its primary outcome. A separate study reported microbiota shifts with microencapsulated butyrate in IBD patients, but without clinical endpoints. Enthusiasm here clearly outruns the data.

  • Tributyrin raises circulating butyrate more effectively than sodium butyrate Moderate evidence

    A double-blind placebo-controlled crossover trial in men with overweight or obesity showed butyrate-enriched triglycerides significantly increased postprandial systemic butyrate concentrations. This validates the pharmacokinetic rationale for the tributyrin form — it is absorbed and hydrolysed rather than consumed in the upper gut — but raising a blood level is not itself a health outcome.

  • Improves IBS symptoms Limited evidence

    Trials mostly test butyrate inside multi-ingredient products. A 2024 RCT of microencapsulated sodium butyrate combined with probiotics and fructooligosaccharides reported symptom improvement in IBS, but the design cannot attribute the effect to butyrate. Butyrate-only IBS trials are small and inconsistent.

  • Fermentable fibre is the better route to colonic butyrate Moderate evidence

    Resistant starch, inulin and beta-glucan reliably raise colonic butyrate production in human trials, and this is where the epidemiological benefits attributed to butyrate are actually observed. Oral butyrate is largely absorbed in the small intestine and reaches the colon in meaningful amounts only if enterically protected — which is why enemas, not capsules, are used in distal colitis research.

Dosage & safety

Studied doseSodium, calcium or magnesium butyrate: 150-600 mg/day of butyrate, usually microencapsulated, in divided doses; some IBD trials used up to 4 g/day of sodium butyrate. Tributyrin: 300-600 mg twice daily with food (tributyrin is roughly 90% butyrate by weight and avoids the sodium load). Butyrate enemas in colitis research use 80-100 mmol/L, 60 mL, once or twice daily — a route oral supplements cannot replicate.
SafetyMild GI upset, nausea and belching are common. The dominant practical problem is the smell and taste — butyric acid is the compound that makes rancid butter and vomit smell as they do; enteric coating and tributyrin esterification largely solve this, and uncoated products are frequently abandoned for that reason. Sodium butyrate delivers a meaningful sodium load at gram doses; calcium and magnesium salts add to those mineral totals. No established drug interactions. It does not substitute for prescribed IBD therapy — none of the trial evidence supports replacing mesalamine, biologics or steroids. Long-term safety data beyond a few months does not exist for any oral form.

Scientific references

Where to buy

Deva, Vegan Tributyrin, 500 mg , 90 Vegan Caps

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Gut health